Investor Relations

Company Overview

Qualigen Therapeutics is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. The investigational compounds within Qualigen’s family of Pan-RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers. Our investigational QN-247 compound inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells; QN-247 may thereby be able to inhibit the cells’ proliferation. QN-247 has shown promise in preclinical studies for the treatment of acute myeloid leukemia (AML).

In July 2023, Qualigen sold its FastPack® diagnostics business to Chembio Diagnostics, Inc., an American subsidiary of French diagnostics provider BIOSYNEX Group, a leader in the design and distribution of rapid tests.

Stock Snapshot

Nasdaq: QLGN

Qualigen Therapeutics, Inc.

Latest Presentation

Industry Classifications

Sector:

Healthcare

SIC:

Pharmaceutical Preparations (2834)

NAICS:

Pharmaceutical Preparation Manufacturing (325412)

Industry:

Biotechnology

Latest News

FAQ

Our stock is traded on the Nasdaq under the symbol QLGN.
Qualigen, Inc. was originally incorporated in Minnesota as a privately held corporation in 1996. Qualigen Therapeutics, Inc. (formerly Ritter Pharmaceuticals, Inc.) was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural Sciences, LLC. In September 2008, the company was converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc. In May 2020, Ritter Pharmaceuticals, Inc. entered into a reverse merger transaction with Qualigen, Inc. pursuant to which Qualigen, Inc. became a wholly-owned subsidiary of Ritter Pharmaceuticals, Inc. Following the reverse merger transaction, Ritter Pharmaceuticals, Inc. changed its name to Qualigen Therapeutics, Inc
June 29, 2015 as Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR). Renamed Qualigen Therapeutics, Inc. on May 22, 2020 (Nasdaq: QLGN).

2042 Corte del Nogal
Suite B
Carlsbad, CA 92011

EQ Shareowner Services
PO Box 64874
St Paul MN 55164
T: 800-468-9716
ShareownerOnline.com

Sign Up For Email Alerts

Receive updates straight into your inbox

Investor Contact Information

Company

Qualigen Therapeutics, Inc.
2042 Corte del Nogal
Suite B
Carlsbad, CA 92011
T: +760-918-9165
F: 760-918-9127
ir@qualigentx.com

Investor Relations

Transfer Agent

EQ Shareowner Services
PO Box 64874
St Paul, MN 55164
T: +8004689716
ShareownerOnline.com